Local accumulation of plasminogen activator inhibitor-1 (PAI-1) in response to thrombosis has been implicated not only in inhibition of fibrinolysis but also in the pathogenesis of vascular disease. To determine whether thrombin, known to be released from thrombi, can induce expression of PAI-1 in vascular smooth muscle, bovine aortic smooth muscle cells were exposed to highly purified bovine thrombin. Thrombin, in the absence of serum, induced production of PAI-1 by bovine aortic smooth muscle cells in a dose-dependent manner. PAI-1 activity in the conditioned media reached a maximum with 12 nM thrombin. Metabolic labeling with [35S] methionine demonstrated that the elaborated PAI-1 was newly synthesized and that it comprised both a cleaved inactive 42-kd form and an uncleaved active 46-kd form. The increase of PAI-1 activity in the media paralleled the thrombin-induced increase in the concentration of the 46-kd form. Preincubation of thrombin with hirudin, a specific inhibitor of thrombin, or with D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone, an inhibitor of the active site of thrombin, prevented the induction of PAI-1 synthesis. The stimulatory effect of thrombin on PAI-1 synthesis was also evident at the level of expression of mRNA, with steady-state PAI-1 mRNA levels increasing by 10io in 4-8 hours. When the bovine aortic smooth muscle cells were exposed to transforming growth factor-13l, an agonist shown previously to increase PAI-1 synthesis in diverse cell types, synergy with thrombin was evident. Thus, production of PAI-1 by vascular smooth muscle cells is augmented by thrombin, potentially predisposing the cells to persistent thrombi and to vasculopathy at sites of thrombosis and at sites of endothelial injury or denudation. (Circulation Research 1993;72:36-43) KEY WoRDs * thrombin * plasminogen activator inhibitor-1 * transforming growth factor-31 vasculopathy * smooth muscle cells A therogenesis involves sequential complex phenomena that often follow endothelial injury. Platelet activation and aggregation, thrombosis, and smooth muscle cell proliferation are prominent.1 Thrombin, a powerful activator of platelets, elicits release of growth factors and chemotactic agents from platelets and intact cells.2 Its potential contribution to atherogenesis is suggested by its presence in thrombi and the extracellular matrix (ECM) within evolving plaques.3 Abnormally high concentrations of thrombin (60-90 nM) are present in blood when intravascular thrombosis is in progress45 and in thrombi that persist after recanalization has been induced with thrombolytic drugs.6 The surfaces of residual thrombi are twofold to fourfold more powerful as stimuli for thrombosis than is the freshly injured arterial wall, partially because of the presence of functionally active thrombin.7,8 When injury to a vessel wall involves denudation of endothelium and the medial smooth muscle cell layer is either exposed or
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Expression of Plasminogen Activator Inhibitor-1 by Thrombin therogenesis involves sequential complex phenomena that often follow endothelial injury. Platelet activation and aggregation, thrombosis, and smooth muscle cell proliferation are prominent. 1 Thrombin, a powerful activator of platelets, elicits release of growth factors and chemotactic agents from platelets and intact cells.2 Its potential contribution to atherogenesis is suggested by its presence in thrombi and the extracellular matrix (ECM) within evolving plaques. 3 Abnormally high concentrations of thrombin (60-90 nM) are present in blood when intravascular thrombosis is in progress45 and in thrombi that persist after recanalization has been induced with thrombolytic drugs. 6 The surfaces of residual thrombi are twofold to fourfold more powerful as stimuli for thrombosis than is the freshly injured arterial wall, partially because of the presence of functionally active thrombin.7,8 When injury to a vessel wall involves denudation of endothelium and the medial smooth muscle cell layer is either exposed or damaged, atherogenesis is accelerated.9 Both proliferation and migration of smooth muscle cells become prominent. 10 Plasminogen activator inhibitor-1 (PAI-1), a serine protease inhibitor (Serpin), is the primary physiological inhibitor of urokinase (u-PA) and tissue-type (t-PA) plasminogen activators.'1 Its importance in modulating fibrinolysis is supported by the correlation of high plasma levels of PAI-1 with an increased incidence of myocardial infarction and deep vein thrombosis.12-14 In addition, it may play a pivotal role in normal and pathological arterial wall remodeling after injury. 15 Thrombin can modify PAI-1 expression in human endothelial cells16'17 and in hepatoma (HepG2) cells in culture. 18 However, its potential effects on the production of PAI-1 in vascular smooth muscle cells have not yet been elucidated. Because such cells are exposed to thrombin in blood and in thrombi when deep vessel injury occurs, we undertook the present study to determine whether thrombin can induce synthesis of PAI-1 in vascular smooth muscle cells in culture.
Materials and Methods Materials
Dulbecco's modified Eagle's medium (DMEM), penicillin/streptomycin (PS) (30 units/ml, 30 ,ug/ml), and lOx trypsin-EDTA were obtained from GIBCO Laboratories, Grand Island, N.Y. DMEM/Ham's nutrient Detection of PAI-1 antigen, PAI-i activity, and t-PA activity in conditioned media. Cells were exposed to highly purified human thrombin in concentrations of 3.0, 6.0, 12, 36, 60, and 120 nM after they had been cultured in DMEM with 1% PS and 10% FBS and allowed to come to confluence in 9.6-cm2 wells (1.0 x 105 cells/cm2). Media were removed, and the cells were washed three times with PBS before being placed in serum-free DMEM/F-12 HEPES media (growth arrest media) for 48 hours. Subsequently, aliquots of fresh growth arrest media containing selected concentrations conditioned media (CM) were collected, supplemented with 0.01% Tween 80, and frozen at -20°C until assay. PAI-1 activity was assayed with the use of S-2251, a chromogenic substrate, by measuring inhibition of activation of plasminogen by t-PA,21 and t-PA activity was assayed by a spectrophotometric solid-phase fibrintissue plasminogen activator assay.22 PAI-1 antigen was quantified by enzyme-linked immunosorbent assay (ELISA) (TintElize, Biopool). 23 In time-course experiments, cells were exposed to thrombin after the selected growth-arrest interval, and aliquots of CM were collected 4, 8, 12, 16, 24, 32 , and 48 hours later.
To define the effects of thrombin on the production of PAI-1 by vascular smooth muscle cells, positive control experiments were performed with TGF-f31 and PDGF, agents known to induce its synthesis. After the growtharrest period, TGF-f31 at concentrations of 0.1, 0.5, and 1.0 ng/ml or PDGF at 10.0 ng/ml were added to the media. In some experiments, growth factors and thrombin were added simultaneously. In others, thrombin was preincubated with hirudin, a specific inhibitor of thrombin, or with PPACK, an active site inhibitor of Serpins, to determine whether the observed effects of thrombin on PAI-1 synthesis by vascular smooth muscle cells required a functionally intact active site.
Quantification (Figure 2, top panel) . However, PAI-1 activity was maximal after exposure of the cells to 12 nM thrombin, as shown in Figure 2 , bottom panel. Thus, the EC50 for thrombin is between 3 and 6 nM. Thrombin at 1.5 nM exerted no effect. approximately 100% (Figure 4) . The 1.6-kb PAI-1 mRNA band was found to contain between 10% and 20% of the total PAI-1 mRNA detected (3.0+1.6 kb). Its concentration increased proportionally with that of the 3.0-kb form. The increase in PAI-1 mRNA is consistent with the view that thrombin augments PAI-1 synthesis at the level of expression of mRNA by increasing transcription, stabilizing PAI-1 transcripts, or both.
Synergistic Effects of Thrombin and Selected Agonists on Production of PAI-1
To determine whether the effects of thrombin were additive or synergistic with those of known stimuli of production of PAI-1 in BASMCs, experiments were performed with PDGF (10.0 ng/ml) and TGF-,f1 (0.5, 1.0, and 10.0 ng/ml) ( Figure 5 ). In contrast to results of studies in which serum was used in CM,29 neither PDGF nor TGF-j81 alone, in the absence of serum, significantly stimulated production of PAI-1 in the BASMCs. However, when thrombin (60 nM) was added to serum-free media containing TGF-f31, a significant increase in production of PAI-1 occurred that exceeded that attributable simply to additive effects ( Figure 6 ). Incubation of cells with thrombin plus anti-TGF-f31 antibodies did not abolish the stimulatory effect of thrombin, indicating that the thrombin effect is not mediated by extracellular TGF-11. 
Importance of the Active Site
Preincubation of thrombin with an active site inhibitor, PPACK, abolished the stimulatory effect of thrombin on production of PAI-1. Hirudin, another thrombin inhibitor, which blocks both the active site and the anion binding exosite, abolished the effect as well. When hirudin was added to serum, the stimulatory effects of serum on PAI-1 appeared to be somewhat diminished ( Figure 7) 
